Bristol-Myers Partner Ono Drops as Cancer Drug Data DisappointBy and
Ono Pharmaceutical Co. shares dropped in Japan trading after its partner Bristol-Myers Squibb Co. released study results for its immune-based therapy Opdivo that fell short of already low expectations in a lung cancer trial that studied wider use of the drug.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Smartphones Are Killing Americans, But Nobody’s Counting
- Turns Out It Will Be Congress’s Fault When Stocks Crash
- Why a Pub in the Middle of Nowhere Was Named the World’s Best Restaurant
- Facebook and Google Helped Anti-Refugee Campaign in Swing States
- Ford to Take $267 Million Hit From Recall of F-Series Trucks